Research shows that two Pfizer vaccine doses offer less protection against Omicron than against Delta

The first major real-world study of how vaccines hold up against Omicron found that two injections from Pfizer Inc. and BioNTech SE’s Covid-19 vaccine reduced the risk of hospitalization by 70% for patients infected with the highly mutated variant.

The study, by South Africa’s largest private health insurer, Discovery Ltd., found that while Omicron reduced the vaccine’s effectiveness against infection to 33% from 80% for Delta, its effect on protection against hospitalization was less pronounced, namely from 93% to 70%.


Leave a Comment